New York State Common Retirement Fund Trims Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Common Retirement Fund trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 131,078 shares of the medical research company’s stock after selling 5,565 shares during the period. New York State Common Retirement Fund owned approximately 0.26% of Charles River Laboratories International worth $30,987,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of CRL. Meritage Group LP acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $173,174,000. Rhenman & Partners Asset Management AB acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $48,603,000. Montrusco Bolton Investments Inc. lifted its stake in shares of Charles River Laboratories International by 35.8% during the third quarter. Montrusco Bolton Investments Inc. now owns 855,387 shares of the medical research company’s stock worth $164,058,000 after buying an additional 225,562 shares during the period. Armistice Capital LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $30,573,000. Finally, abrdn plc lifted its stake in shares of Charles River Laboratories International by 872.0% during the fourth quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock worth $28,795,000 after buying an additional 109,275 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Argus boosted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Robert W. Baird increased their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. UBS Group upped their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Citigroup upped their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Finally, Guggenheim downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $253.23.

Charles River Laboratories International Stock Down 4.9 %

CRL stock opened at $227.67 on Friday. The company has a market cap of $11.73 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.88 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company’s 50-day moving average price is $253.80 and its 200 day moving average price is $222.39. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm’s revenue was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.98 earnings per share. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Insider Activity

In other news, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 over the last 90 days. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).